Antidepressant drugs in children and adolescents: Analytical and demographic data in a naturalistic, clinical study

Journal of Clinical Psychopharmacology

Volumn 31, Issue 1, 2011, Pages 98-102

  Chermá, Maria D ^a   Ahlner, Johan ^a,b   Bengtsson, Finn ^a   Gustafsson, Per A ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b DEPARTMENT OF FORENSIC GENETICS AND FORENSIC TOXICOLOGY   (Sweden)

Author keywords

antidepressants; dosage; pediatrics; serum concentration; therapeutic drug monitoring

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 2D6; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NORSERTRALINE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADOLESCENT; ADULT; ANXIETY; ARTICLE; ASTHENIA; BODY MASS; CHILD; CHILD PSYCHIATRY; DEMOGRAPHY; DEPRESSION; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NATURALISTIC INQUIRY; NAUSEA; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; SWEDEN; TREMOR; XEROSTOMIA;

ADOLESCENT; AGE FACTORS; ANTIDEPRESSIVE AGENTS; CHILD; COHORT STUDIES; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; SWEDEN; YOUNG ADULT;

EID: 78651289168     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318205e66d     Document Type: Article

References (30)

1. Ustun TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;184: 386-392.
2. Costello EJ, Angold A, Burns BJ, et al. The Great Smoky Mountains Study of Youth. Goals, design, methods, and the prevalence of DSM-III-R disorders. Arch Gen Psychiatry. 1996;53:1129-1136.
3. FASS. The Swedish Physician's Desk Reference. Stockholm, Sweden: The Swedish Association of the Pharmaceutical Industry; 2001-2004.
4. Barbui C, Hotopf M. Forty years of antidepressant drug trials. Acta Psychiatr Scand. 2001;104:92-95.
5. Ahlgren T. Kraftig ökning av antidepressiva läkemedel till barn och ungdomar. Nya mediciner bidrar starkt till stigande lä kemedelskostnader. Läkartidningen. 2000;97:2592.
6. Statistics Sweden: Ö rebro, Sweden. Available at: http://www.scb.se/ Pages/PublishingCalendarViewInfo-259923.aspx? PublObjId=1759. Accessed September 15, 2009.
7. Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau". Ther Drug Monit. 2004;26:145-151.
8. Reis M, Lundmark J, Bjork H, et al. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit. 2002;24:545-553.
9. Lundmark J, Reis M, Bengtsson F. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. Ther Drug Monit. 2000;22:446-454.
10. Baumann P, Ulrich S, Eckermann G, et al. The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. Dialogues Clin Neurosci. 2005;7:231-247.
11. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
12. Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997. Ther Drug Monit. 2003;25:183-191.
13. Reis M, Prochazka J, Sitsen A, et al. Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study. Ther Drug Monit. 2005;27: 469-477.
14. Reis M, Aberg-Wistedt A, Agren H, et al. Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol. 2004;19:283-291.
15. Lundmark J, Reis M, Bengtsson F. Serum concentrations of fluoxetine in the clinical treatment setting. Ther Drug Monit. 2001;23:139-147.
16. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473.
17. Carlsson B, Norlander B. Solid-phase extraction with end-capped C2 columns for the routine measurement of racemic citalopram and metabolites in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997;702:234-239.
18. Carlsson B, Olsson G, Reis M, et al. Enantioselective analysis of citalopram and metabolites in adolescents. Ther Drug Monit. 2001;23:658-664.
19. Bjork H, Bengtsson F. A simple method for routine TDM of the SSRI sertraline and desmethylsertraline in serum by HPLC. Eur Neuropsychopharmacol. 1997;7:S138.
20. Zackrisson AL, Lindblom B. Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing. Eur J Clin Pharmacol. 2003;59:521-526.
21. Soderback E, Zackrisson AL, Lindblom B, et al. Determination of CYP2D6 gene copy number by pyrosequencing. Clin Chem. 2005;51:522-531.
22. Growth reference data for children and adolescents, 5-19 years. World Health Organization. Accessed August 31, 2009.
23. Reis M, Aamo T, Spigset O, et al. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit. 2009;31:42-56.
24. Alderman J, Wolkow R, Chung M, et al. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry. 1998;37:386-394.
25. Geller DA, Wagner KD, Emslie G, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2004;43:1387-1396.
26. Thomsen PH, Ebbesen C, Persson C. Long-term experience with citalopram in the treatment of adolescent OCD. J Am Acad Child Adolesc Psychiatry. 2001;40:895-902.
27. Reis M, Cherma MD, Carlsson B, et al. Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit. 2007;29:758-766.
28. Cherma MD, Lofgren UB, Almkvist G, et al. Assessment of the prescription of antidepressant drugs in elderly nursing home patients: a clinical and laboratory follow-up investigation. J Clin Psychopharmacol. 2008;28:424-431.
29. Zackrisson AL, Lindblom B, Ahlner J. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther. 2010;88: 354-359.
30. Serradell J, Galle B. Prescribing for unlabeled indications. HMO Pract. 1993;7:44-47.